OmniAb (NASDAQ:OABI) Chief Financial Officer Kurt Gustafson outlined the company’s antibody-discovery platform, partner pipeline and revenue model during a company presentation, emphasizing a strategy built around licensing technology to pharmaceutical and biotechnology companies rather than developing drugs internally. Gustafson said OmniAb engineers transgenic animals whose immune systems produce fully human antibodies in response to foreign […]